Pharmacy Law Ethics .
Added on 2023-05-28
4 Pages671 Words434 Views
|
|
|
Running head: PHARMACY LAW ETHICS
Pharmacy law ethics
Name of the Student
Name of the university
Author Note
Pharmacy law ethics
Name of the Student
Name of the university
Author Note
1PHARMACY LAW ETHICS
There are a few new drugs that caused serious reaction after getting approval. So,
physicians recommended not to consume a drug at least after 5 years of patient trial. However,
almost 1.9 million hospitalization in a year occurred even after properly prescribed drug
consumption. 2.74 million of adverse drug reaction occurred in total in a year and 128000
people had died by prescribed drug reactions. This causes prescription drugs to be a major cause
of health risk and stoke had become 4th leading cause of death. According to report of European
commission, adverse drugs from prescription causes almost 328000 patients died in US and
Europe in a year. However, FDA acknowledges a few fractions of that cases. Almost 170 million
American patients take prescribed drugs and among them 80% is generic. However, patients,
who take new patented drugs are, only able to generate modest benefits over old drugs. A very
small number of drugs (11-15%) are capable of giving advantageous effect to the patient over the
pre-established drugs. Almost 4/5th of $70 billion was spend on slightly new variation of drugs.
In between 2002 to 2011, the researcher of France, the Netherlands and Canada had reported
that, 8% of new drugs were effective in nature (Light, 2014). Therapeutically similar drugs had
advantages like some patients may respond to a new drugs same class instead of old ones. The
main benefit of testing drugs is to identify specific patients who might get benefit from that drug.
Most of the significant discoveries resulted in clinical advancement. Silvio Garattini told “When
a major discovery actually helps patients, we feel very lucky.”
Introducing more number of minor variants of drug is not for the patient advancement and it is
just a marketing strategy. Jerry Avon told that laws for meaningful innovation are giving more
profit than medical advancement. Marc-Andre Gagnon has shown that net return on revenue has
enhanced 2.5 times to 3.2 times due to high price and more prescription by the physicians.
There are a few new drugs that caused serious reaction after getting approval. So,
physicians recommended not to consume a drug at least after 5 years of patient trial. However,
almost 1.9 million hospitalization in a year occurred even after properly prescribed drug
consumption. 2.74 million of adverse drug reaction occurred in total in a year and 128000
people had died by prescribed drug reactions. This causes prescription drugs to be a major cause
of health risk and stoke had become 4th leading cause of death. According to report of European
commission, adverse drugs from prescription causes almost 328000 patients died in US and
Europe in a year. However, FDA acknowledges a few fractions of that cases. Almost 170 million
American patients take prescribed drugs and among them 80% is generic. However, patients,
who take new patented drugs are, only able to generate modest benefits over old drugs. A very
small number of drugs (11-15%) are capable of giving advantageous effect to the patient over the
pre-established drugs. Almost 4/5th of $70 billion was spend on slightly new variation of drugs.
In between 2002 to 2011, the researcher of France, the Netherlands and Canada had reported
that, 8% of new drugs were effective in nature (Light, 2014). Therapeutically similar drugs had
advantages like some patients may respond to a new drugs same class instead of old ones. The
main benefit of testing drugs is to identify specific patients who might get benefit from that drug.
Most of the significant discoveries resulted in clinical advancement. Silvio Garattini told “When
a major discovery actually helps patients, we feel very lucky.”
Introducing more number of minor variants of drug is not for the patient advancement and it is
just a marketing strategy. Jerry Avon told that laws for meaningful innovation are giving more
profit than medical advancement. Marc-Andre Gagnon has shown that net return on revenue has
enhanced 2.5 times to 3.2 times due to high price and more prescription by the physicians.
End of preview
Want to access all the pages? Upload your documents or become a member.